Lung Cancer | Specialty

Agents Targeting ROS1 Gain Traction in NSCLC

May 1st 2020

The past 2 decades have been transformative for the treatment of non–small cell lung cancer; two-thirds of patients have been found to harbor molecular drivers, and a growing proportion of these are now targetable with FDA-approved drugs.

Cell-Free DNA Detects Adjuvant MRD Positivity and Disease Relapse in NSCLC

April 29th 2020

Circulating tumor DNA may be a biomarker for the detection of postsurgical minimal residual disease and for determining the clonality of relapsing disease.

TIL Therapy Elicits Encouraging Activity in Advanced NSCLC

April 29th 2020

Adoptive cell transfer with tumor-infiltrating lymphocytes was found to be feasible, have a manageable toxicity profile, and expanded in 95% of patients with metastatic non–small cell lung cancer who had disease progression on nivolumab (Opdivo).

Poziotinib Shows Mixed Findings in Exon 20-Mutant NSCLC

April 28th 2020

Patients with pretreated non–small cell lung cancer and EGFR exon 20 insertions demonstrated a 68.7% disease control rate while on poziotinib systemic therapy.

Capmatinib Shows Clinical Meaningful Activity and Intracranial Responses in MET Exon 14+ NSCLC

April 28th 2020

Results from the GEOMETRY mono-1 study demonstrated antitumor efficacy of and deep and durable responses with capmatinib in 97 patients with advanced non–small cell lung cancer who harbor MET exon 14 mutations.

FDA Grants Mobocertinib Breakthrough Designation for EGFR Exon 20–Mutant NSCLC

April 27th 2020

Mobocertinib (TAK-788) has received an FDA breakthrough therapy designation for the treatment of patients with EGFR exon 20-mutant non–small cell lung cancer.

Cemiplimab Improves Survival in Frontline PD-L1–High NSCLC

April 27th 2020

The PD-1 inhibitor cemiplimab significantly improved overall survival as a frontline treatment for patients with high–PD-L1 non–small cell lung cancer.

Sintilimab Plus Pemetrexed Frontline NSCLC Application Accepted in China

April 24th 2020

The National Medical Products Administration of China has accepted an application for the PD-1 inhibitor sintilimab injection for use in combination with pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer.

Tislelizumab Frontline Combo Takes Step Toward Chinese Approval in Squamous NSCLC

April 21st 2020

The China National Medical Products Administration has accepted a supplemental new drug application for the PD-1 inhibitor tislelizumab for use in combination with chemotherapy for the first-line treatment of patients with advanced squamous non–small cell lung cancer.

Nivolumab Plus Ipilimumab Improves Survival in Frontline Mesothelioma

April 20th 2020

Nivolumab combined with ipilimumab significantly improved overall survival versus chemotherapy in previously untreated patients with malignant pleural mesothelioma.

Managing Lung Cancer Patients Through the COVID-19 Crisis: What to Know

April 15th 2020

Join oncologists nationwide who have learned from the top leaders in the lung cancer field as they share their insights on coronavirus disease 2019 and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system. Join us Thursday, May 28, 2020 at 8 PM EST.

Tislelizumab Frontline Combo Improves PFS in Nonsquamous NSCLC

April 14th 2020

The PD-1 inhibitor tislelizumab combined with frontline chemotherapy significantly improved progression-free survival versus chemotherapy alone in patients with nonsquamous non–small cell lung cancer.

The Future of Lung Cancer Management

April 13th 2020

Limited-Stage SCLC: Is Immunotherapy an Option?

April 13th 2020

Small-Cell Lung Cancer: The IMpower133 and CASPIAN trials

April 13th 2020

Stage III NSCLC Progression Treatment Strategy

April 13th 2020

Stage III NSCLC: When to Start Durvalumab

April 13th 2020

Unresectable Stage III Lung Cancer Management

April 13th 2020

Brain Metastatic NSCLC: Targeted Therapy Approach

April 13th 2020

ALK-Rearranged & MET Exon 14 NSCLC Treatment Options

April 13th 2020